Peptides as a therapeutic strategy against Klebsiella pneumoniae

Trends Pharmacol Sci. 2022 Apr;43(4):335-348. doi: 10.1016/j.tips.2021.12.006. Epub 2022 Jan 22.

Abstract

Increasing levels of resistance to conventional antibiotics have led to a search for new therapeutic options against bacterial infections. Klebsiella pneumoniae is considered a world health problem due to high levels of mortality associated with resistance to multiple antibiotics. Antimicrobial peptides (AMPs) have showed activity against this bacterium, which makes them a promising alternative in tackling resistance. In this article, we carried out an overview of the recent development of AMPs against K. pneumoniae using different designs and acting by different mechanisms, such as a recently proposed one against capsulated strains. Moreover, we outline AMPs' therapeutic potential when tested in combination with conventional antibiotics and against biofilms. Furthermore, challenges and perspectives for applying AMPs in clinical practice are discussed here.

Keywords: bacterial resistance; biofilms; combination therapy; therapy, antibiotics.

Publication types

  • Research Support, Non-U.S. Gov't
  • Review

MeSH terms

  • Anti-Bacterial Agents / pharmacology
  • Anti-Bacterial Agents / therapeutic use
  • Antimicrobial Cationic Peptides* / pharmacology
  • Antimicrobial Cationic Peptides* / therapeutic use
  • Biofilms
  • Humans
  • Klebsiella pneumoniae*
  • Microbial Sensitivity Tests

Substances

  • Anti-Bacterial Agents
  • Antimicrobial Cationic Peptides